Caligan Partners LP
Known title: DirectorCIK: 0001727492
Caligan Partners LP's purchase track record
How the stock did after each of Caligan Partners LP's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
12
of 13 since April 6, 2022
Stock higher 6 months later
50%
3 months: 38%
Median 6-month return
-6.0%
3 months: -16.7%
Beat the S&P 500
50%
median +3.3% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 5/19/2026 | LQDA | $318K | +23.9% | pending | — |
| 8/30/2024 | LQDA | $1.43M | +21.4% | +62.9% | +5.4% |
| 12/14/2023 | LQDA | $8.00M | +110.1% | +84.2% | +15.1% |
| 9/6/2022 | LQDA | $1.41M | -3.6% | +25.1% | +2.0% |
| 7/29/2022 | LAB | $1.48M | -22.1% | +46.9% | -1.5% |
| 6/13/2022 | LAB | $170K | -16.7% | -23.0% | +6.4% |
| 6/2/2022 | LAB | $879K | -28.1% | -28.1% | -2.4% |
| 5/25/2022 | LQDA | $270K | +103.8% | +34.0% | +1.2% |
| 5/17/2022 | LQDA | $1.30M | +24.0% | -19.0% | -2.4% |
| 5/6/2022 | LAB | $1.41M | -35.9% | -62.0% | -8.6% |
| 4/28/2022 | LAB | $1.08M | -47.3% | -56.5% | -11.2% |
| 4/18/2022 | LQDA | $9.00M | -27.4% | +7.0% | -16.3% |
| 4/6/2022 | LAB | $2.66M | -55.5% | -65.5% | -15.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| LQDA | ▼ Sell | Open Market | 5,300 | $318K | 5/19/2026 | View on chart |
| LQDA | ▲ Buy | Open Market | 5,300 | $318K | 5/19/2026 | View on chart |
| LQDA | ▲ Buy | Grant | 1,123,595 | $10.0M | 9/12/2024 | View on chart |
| LQDA | ▼ Sell | Open Market | 150,000 | $1.4M | 8/30/2024 | View on chart |
| LQDA | ▲ Buy | Open Market | 150,000 | $1.4M | 8/30/2024 | View on chart |
| LQDA | ▼ Sell | Other | 3,440,948 | — | 8/30/2024 | View on chart |
| LQDA | ▲ Buy | Open Market | 1,117,318 | $8.0M | 12/14/2023 | View on chart |
| LAB | ▼ Sell | Other | 670,466 | — | 7/3/2023 | View on chart |
| LAB | ▼ Sell | Other | 108,879 | — | 6/29/2023 | View on chart |
| LAB | ▼ Sell | Other | 2,868,037 | — | 12/29/2022 | View on chart |
| LQDA | ▲ Buy | Open Market | 250,000 | $1.4M | 9/6/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 255,173 | $447K | 8/4/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 46,009 | $80K | 8/3/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 272,618 | $447K | 8/2/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 210,200 | $311K | 8/1/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 137,648 | $195K | 7/29/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 100,000 | $170K | 6/13/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 250,000 | $495K | 6/3/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 200,000 | $384K | 6/2/2022 | View on chart |
| LQDA | ▲ Buy | Open Market | 79,400 | $270K | 5/25/2022 | View on chart |
| LQDA | ▲ Buy | Open Market | 85,000 | $494K | 5/19/2022 | View on chart |
| LQDA | ▲ Buy | Open Market | 76,404 | $450K | 5/18/2022 | View on chart |
| LQDA | ▲ Buy | Open Market | 59,700 | $358K | 5/17/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 25,000 | $63K | 5/10/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 463,350 | $1.3M | 5/6/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 125,000 | $351K | 5/2/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 247,400 | $658K | 4/29/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 27,600 | $66K | 4/28/2022 | View on chart |
| LQDA | ▲ Buy | Open Market | 1,764,705 | $9.0M | 4/18/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 50,000 | $180K | 4/12/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 145,000 | $561K | 4/11/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 200,000 | $752K | 4/8/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 200,000 | $776K | 4/7/2022 | View on chart |
| LAB | ▲ Buy | Open Market | 109,573 | $394K | 4/6/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
Liquidia shares fall on patent court loss and analyst downgrades
Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.
Liquidia shares fall on patent court loss and analyst downgrades. Liquidia stock is down sharply after a court ruling regarding YUTREPIA patent access, which analysts say clouds the drug's future. Wells Fargo downgraded the stock to Equal-Weight and lowered its price target to $30, while other analysts also cut their targets. The stock is currently trading near its 52-week low, reflecting significant market concern over the legal outcome.